The startup is using CRISPR tools to stop errant expression of a gene linked to facioscapulohumeral muscular dystrophy, a disorder on the radars of several drugmakers.
Epicrispr Biotechnologies to Begin Clinical Trials for its Lead Epigenetic Therapy for FSHD Patients
The therapy, EPI-321, is intended to treat cases of facioscapulohumeral muscular dystrophy, a genetic neuromuscular disorder.
The collaboration between Muscular Dystrophy UK, the leading charity for over 110,000 people in the UK living with one of ...
7don MSN
An 8-year-old northern Minnesota boy is one of the first in the country to receive a specific type of gene therapy treatment.
Patients with myotonic dystrophy face unique challenges in managing their ... 1-2 Recent studies presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference shed ...
A patient has died while taking a closely watched gene therapy for muscular dystrophy. Sarepta Therapeutics announced the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback